

# Elisabetta Orlandini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8807620/publications.pdf>

Version: 2024-02-01

89  
papers

1,563  
citations

257101

24  
h-index

377514

34  
g-index

100  
all docs

100  
docs citations

100  
times ranked

2054  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and Evaluation of Monoaryl Derivatives as Transthyretin Fibril Formation Inhibitors. <i>Pharmaceutical Chemistry Journal</i> , 2022, 56, 38-47.	0.3	2
2	Nature-Inspired O-Benzyl Oxime-Based Derivatives as New Dual-Acting Agents Targeting Aldose Reductase and Oxidative Stress. <i>Biomolecules</i> , 2022, 12, 448.	1.8	11
3	Antioxidant Quercetin 3-O-Glycosylated Plant Flavonols Contribute to Transthyretin Stabilization. <i>Crystals</i> , 2022, 12, 638.	1.0	3
4	Activation of carbonic anhydrases from human brain by amino alcohol oxime ethers: towards human carbonic anhydrase VII selective activators. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 48-57.	2.5	12
5	Application of PROTAC strategy to TTR- $\text{A}\beta^2$ protein-protein interaction for the development of Alzheimer's disease drugs. <i>Neural Regeneration Research</i> , 2021, 16, 1554.	1.6	10
6	Neuroglobin and neuroprotection: the role of natural and synthetic compounds in neuroglobin pharmacological induction. <i>Neural Regeneration Research</i> , 2021, 16, 2353.	1.6	12
7	Natural Marine and Terrestrial Compounds as Modulators of Matrix Metalloproteinases-2 (MMP-2) and MMP-9 in Alzheimer's Disease. <i>Pharmaceuticals</i> , 2021, 14, 86.	1.7	26
8	Physiological Metals Can Induce Conformational Changes in Transthyretin Structure: Neuroprotection or Misfolding Induction?. <i>Crystals</i> , 2021, 11, 354.	1.0	9
9	Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives. <i>Molecules</i> , 2021, 26, 6380.	1.7	27
10	Multifunctional Small Molecules as Potential Anti-Alzheimer's Disease Agents. <i>Molecules</i> , 2021, 26, 6015.	1.7	7
11	Novel tacrine-benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer's Disease. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 211-226.	2.5	39
12	Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115673.	1.4	8
13	Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 1145-1162.	2.5	35
14	Oxy-imino saccharidic derivatives as a new structural class of aldose reductase inhibitors endowed with anti-oxidant activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 1194-1205.	2.5	5
15	Focus on Human Monoamine Transporter Selectivity. New Human DAT and NET Models, Experimental Validation, and SERT Affinity Exploration. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3214-3232.	1.7	12
16	Synthesis and investigation of polyhydroxylated pyrrolidine derivatives as novel chemotypes showing dual activity as glucosidase and aldose reductase inhibitors. <i>Bioorganic Chemistry</i> , 2019, 92, 103298.	2.0	13
17	Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP). <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 196-207.	1.4	9
18	Age-related Macular Degeneration: Current Knowledge of Zinc Metalloproteinases Involvement. <i>Current Drug Targets</i> , 2019, 20, 903-918.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4421-4435.	2.9	34
20	Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5804-5815.	1.4	14
21	Copper mediated amyloid- $\beta$ binding to Transthyretin. <i>Scientific Reports</i> , 2018, 8, 13744.	1.6	26
22	Comparison of helical scan and standard rotation methods in single-crystal X-ray data collection strategies. <i>Journal of Synchrotron Radiation</i> , 2017, 24, 42-52.	1.0	27
23	Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 293-298.	1.3	13
24	N-(Aroyl)-N-(arylmethoxy)- $\beta$ -alanines: Selective inhibitors of aldose reductase. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 3068-3076.	1.4	13
25	Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 890-899.	2.6	24
26	Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds. <i>ChemMedChem</i> , 2016, 11, 1865-1874.	1.6	16
27	Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR). <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 40-51.	2.5	15
28	Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 Inhibitors. <i>ChemMedChem</i> , 2016, 11, 1626-1637.	1.6	36
29	A new crystal form of human transthyretin obtained with a curcumin derived ligand. <i>Journal of Structural Biology</i> , 2016, 194, 8-17.	1.3	18
30	X-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 824-833.	2.5	10
31	Synthesis and cyclooxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compounds. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 30, 406-412.	2.5	6
32	<i>N</i> -Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7224-7240.	2.9	54
33	Structural Insights on Carbonic Anhydrase Inhibitory Action, Isoform Selectivity, and Potency of Sulfonamides and Coumarins Incorporating Arylsulfonylureido Groups. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9152-9167.	2.9	55
34	Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell Models. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8089-8103.	2.9	19
35	Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 379-394.	2.6	38
36	Synthesis and Preliminary Evaluation in Tumor Bearing Mice of New <sup>18</sup> F-Labeled Arylsulfone Matrix Metalloproteinase Inhibitors as Tracers for Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2676-2689.	2.9	17

#	ARTICLE	IF	CITATIONS
37	Tafamidis (Vyndaqel): A Light for FAP Patients. <i>ChemMedChem</i> , 2013, 8, 1617-1619.	1.6	16
38	TTR Fibril Formation Inhibitors: Is there a SAR?. <i>Current Medicinal Chemistry</i> , 2012, 19, 2356-2379.	1.2	25
39	Tricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit $\text{I}^{\pm}$ - and $\text{I}^2$ -Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 Isoforms. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9619-9629.	2.9	35
40	A new D2 dopamine receptor agonist allosterically modulates A2A adenosine receptor signalling by interacting with the A2A/D2 receptor heteromer. <i>Cellular Signalling</i> , 2012, 24, 951-960.	1.7	16
41	Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 825-834.	2.6	15
42	Spirotetrahydronaphthalene analogues of sympathomimetic catecholamines. Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-3- $\text{I}^2$ -piperidines]. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 54, 649-660.	1.2	0
43	Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 1057-1066.	1.2	7
44	Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor- $\text{I}^{\pm}$ Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell Models. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2622-2635.	2.9	37
45	Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. <i>Neuroscience</i> , 2010, 168, 514-522.	1.1	49
46	Different Binding Modes of Structurally Diverse Ligands for Human D3DAR. <i>Journal of Chemical Information and Modeling</i> , 2010, 50, 2162-2175.	2.5	3
47	Novel Transthyretin Amyloid Fibril Formation Inhibitors: Synthesis, Biological Evaluation, and X-Ray Structural Analysis. <i>PLoS ONE</i> , 2009, 4, e6290.	1.1	34
48	<i>N</i> -Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4757-4773.	2.9	60
49	Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6347-6361.	2.9	49
50	Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 1057-1066.	1.2	2
51	Synthesis and 5-HT <sub>2A</sub> , 5-HT <sub>1A</sub> and $\text{I}^{\pm}$ 1-Binding Affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-Hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-Hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) Benzyl Oximes. <i>Archiv Der Pharmazie</i> , 2007, 340, 135-139.	2.1	2
52	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 2298-2311.	1.4	44
53	A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 2311-2314.	1.0	23
54	<i>N</i> -Propoxy- <i>N</i> -biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1321-1326.	1.0	38

#	ARTICLE	IF	CITATIONS
55	Synthesis and COX-2 inhibitory properties of N-phenyl- and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene and isoxazole analogs. <i>Il Farmaco</i> , 2004, 59, 25-31.	0.9	33
56	Synthesis and antimicrobial activity of new 7 <sup>12</sup> -(benzo[a]dihydrocarbazolyloxyacetyl)-substituted cephalosporins. <i>Il Farmaco</i> , 2004, 59, 691-696.	0.9	4
57	Synthesis and Prostaglandin Synthase Inhibitory Activity of New Aromatic O-Alkyloxime Ethers Substituted with Methylsulfonamido or Methylsulfonyl Groups on Their Aliphatic Portion.. <i>ChemInform</i> , 2004, 35, no.	0.1	0
58	Synthesis and COX-2 Inhibitory Properties of N-Phenyl- and N-Benzyl-Substituted Amides of 2-(4-Methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic Acid and of Their Pyrazole, Thiophene and Isoxazole Analogues.. <i>ChemInform</i> , 2004, 35, no.	0.1	1
59	New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 2441-2450.	1.4	79
60	Synthesis and prostaglandin synthase inhibitory activity of new aromatic O-alkyloxime ethers substituted with methylsulfonamido or methylsulfonyl groups on their aliphatic portion. <i>Il Farmaco</i> , 2003, 58, 707-714.	0.9	3
61	Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethoxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring. <i>European Journal of Medicinal Chemistry</i> , 2003, 38, 157-168.	2.6	35
62	New N-n-Propyl-Substituted 3-Aryl- and 3-Cyclohexylpiperidines as Partial Agonists at the D4 Dopamine Receptor. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 161-168.	2.9	36
63	Conformationally restrained analogues of sympathomimetic catecholamines. <i>European Journal of Medicinal Chemistry</i> , 2002, 37, 11-22.	2.6	4
64	(E)-[2-(4-Methylsulphonylphenyl)-1-cyclopentenyl-1-methylidene](arylmethoxy)amines. Methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: synthesis and biological properties. <i>European Journal of Medicinal Chemistry</i> , 2002, 37, 391-398.	2.6	13
65	Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties. <i>European Journal of Medicinal Chemistry</i> , 2002, 37, 585-594.	2.6	6
66	Synthesis and inhibitory activity towards human leukocyte elastase of new 7 <sup>1±</sup> -methoxy and 7 <sup>1±</sup> -chloro (2-acyloxymethyl) cephem derivatives. <i>European Journal of Medicinal Chemistry</i> , 2001, 36, 185-193.	2.6	6
67	Enantiopure 3-(arylmethylidene)aminoxy-2-methylpropionic acids: synthesis and antiinflammatory properties. <i>European Journal of Medicinal Chemistry</i> , 2001, 36, 799-807.	2.6	8
68	Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 223-226.	1.0	8
69	Synthesis, inhibitory activity towards human leukocyte elastase and molecular modelling studies of 1-carbamoyl-4-methyleneaminoxazetidinones. <i>European Journal of Medicinal Chemistry</i> , 2000, 35, 53-67.	2.6	15
70	Synthesis and antiviral properties of 9-[(2-methyleneaminoxymethoxy)methyl]guanine derivatives as novel Acyclovir analogues. <i>Il Farmaco</i> , 2000, 55, 104-108.	0.9	5
71	Synthesis and antimicrobial properties of cephalosporin derivatives substituted on the C(7) nitrogen with arylmethoxyimino or arylmethoxyamino alkanoyl groups. <i>Il Farmaco</i> , 1999, 54, 224-231.	0.9	6
72	Synthesis and aldose reductase inhibitory activity of new N-(benzyloxy) glycine derivatives. <i>Il Farmaco</i> , 1998, 53, 369-373.	0.9	5

#	ARTICLE	IF	CITATIONS
73	Synthesis and $\alpha$ -adrenergic and $\alpha$ -imidazoline activity of 3-phenylpiperidines dimethyl-substituted on the phenyl ring. <i>European Journal of Medicinal Chemistry</i> , 1998, 33, 911-919.	2.6	6
74	N-n-Propyl-Substituted 3-(Dimethylphenyl)piperidines Display Novel Discriminative Properties between Dopamine Receptor Subtypes: A Synthesis and Receptor Binding Studies. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4933-4938.	2.9	12
75	New $\beta$ -lactam monocyclic inhibitors of human elastases: Synthesis and anti-elastase properties of 1-carbamoyl-4-methyleneaminoxazetidinone derivatives. <i>European Journal of Medicinal Chemistry</i> , 1997, 32, 889-894.	2.6	6
76	Synthesis and $\alpha$ -adrenergic activity of 2- and 6-methyl-substituted (3,4-dihydroxyphenyl)-3-piperidinols. <i>European Journal of Medicinal Chemistry</i> , 1997, 32, 231-240.	2.6	10
77	Synthesis and antimicrobial activity of 7 beta-(S)- and 7 beta-[(R)-3-(methyleneaminox)-2-methylpropionamido]substituted cephalosporanic acid derivatives. <i>Il Farmaco</i> , 1996, 51, 283-6.	0.9	2
78	Role of the benzylic hydroxyl group of adrenergic catecholamines in eliciting $\alpha$ -adrenergic activity. Synthesis and $\alpha$ -1- and $\alpha$ -2-adrenergic activity of 3-phenyl-3-piperidinols and their desoxy analogs. <i>European Journal of Medicinal Chemistry</i> , 1995, 30, 869-880.	2.6	9
79	Synthesis and adrenergic beta-blocking activity of ortho-, meta- and para-oxypropanolamino-substituted [(benzylideneamino)oxy]propanolamines. <i>Il Farmaco</i> , 1995, 50, 239-43.	0.9	2
80	Synthesis and antimicrobial activity of 7 beta-[N-(arylmethoxyimino) acetamido]cephalosporanic acid derivatives. <i>Il Farmaco</i> , 1995, 50, 713-8.	0.9	6
81	Conformationally restrained $\beta$ -blocking oxime ethers. 2. Synthesis and $\beta$ -adrenergic properties of diastereoisomeric anti and syn 2-(5 $\beta$ -(3 $\beta$ -aryl-substituted)isoxazolidinyl)-N-alkylethanolamines. <i>European Journal of Medicinal Chemistry</i> , 1994, 29, 855-867.	2.6	7
82	Synthesis, antiinflammatory activity and molecular orbital studies of a series of benzylideneaminoxpropionic acids substituted on the phenyl ring. <i>European Journal of Medicinal Chemistry</i> , 1994, 29, 33-39.	2.6	11
83	Synthesis and aldose reductase inhibitory activity of N-(arylsulfonyl)- and N-(aroyl)-N-(arylmethoxy)glycines. <i>European Journal of Medicinal Chemistry</i> , 1994, 29, 787-794.	2.6	17
84	Synthèses et propriétés antimicrobiennes de (E)-3-aminox-2-méthoxyimino propionyl pénicillines et céphalosporines. <i>European Journal of Medicinal Chemistry</i> , 1990, 25, 227-233.	2.6	21
85	Molecular design, synthesis, and antiinflammatory activity of a series of .beta.-aminoxpropionic acids. <i>Journal of Medicinal Chemistry</i> , 1990, 33, 1423-1430.	2.9	22
86	Synthesis and antimicrobial properties of substituted 3-aminoxpropionyl and 3-aminox-(E)-2-méthoxyimino propionyl monobactams. <i>Il Farmaco</i> , 1990, 45, 879-88.	0.9	3
87	Synthèse et propriétés anti-microbiennes des nouveaux dérivés céphalés et pénicillines avec le groupe carboxylique dans la configuration $\beta$ . <i>European Journal of Medicinal Chemistry</i> , 1989, 24, 573-577.	2.6	1
88	Synthesis and antimicrobial properties of substituted .beta.-aminoxpropionyl penicillins and cephalosporins. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 1398-1401.	2.9	20
89	Synthesis and evaluation of the pharmacological activity of rigid analogs of sympathomimetic catecholamines derived from bicyclo[2.2.1]heptane. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 856-859.	2.9	8